Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Feb 26, 2016; 8(2): 120-131
Published online Feb 26, 2016. doi: 10.4330/wjc.v8.i2.120
Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background
Giulia Ganzetti, Anna Campanati, Elisa Molinelli, Annamaria Offidani
Giulia Ganzetti, Anna Campanati, Elisa Molinelli, Annamaria Offidani, Dermatological Unit, Department of Clinical and Molecular Sciences, Polytehnic Marche University, 60126 Ancona, Italy
Author contributions: Ganzetti G, Campanati A and Molinelli E wrote the paper; Offidani A supervised the work.
Conflict-of-interest statement: All authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Giulia Ganzetti, MD, PhD, Dermatological Unit, Department of Clinical and Molecular Sciences, Polytehnic Marche University, Via Conca, 71, 60126 Ancona, Italy. giulia.ganzetti@alice.it
Telephone: +39-71-5965686 Fax: +39-71-5963446
Received: April 28, 2015
Peer-review started: May 6, 2015
First decision: July 22, 2015
Revised: October 8, 2015
Accepted: December 17, 2015
Article in press: December 18, 2015
Published online: February 26, 2016
Core Tip

Core tip: The review focuses on recent scientific data regarding the multiple physio-pathogenetic aspects of the possible link between psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease. The multidisciplinary approach to psoriatic patients appears mandatory to treat concomitant psoriasis-related comorbidity, and the risk/benefit of both biologic and non-biologic therapies should be evaluated.